Marlborough biopharma names inaugural chief commercial officer
Photo I Courtesy of Sumitomo Pharma America
Kenton Stewart, chief commercial officer of Sumitomo Pharma America in Marlborough
Marlborough-based pharmaceutical company Sumitomo Pharma America has selected executive Kenton Stewart as the firm’s inaugural chief commercial officer, effective Oct. 1.
Having previously served as SMPA’s senior vice president, head of sales and market access, Stewart will lead several of the company’s major initiatives including sales, marketing, and commercial operations in his new role, according to a Monday press release from Sumitomo.
“Kenton is well regarded in the industry and has led high performing teams while demonstrating his capabilities in building and nurturing company culture,” Tsutomu Nakagawa, SMPA president and CEO, said in the release. “I am confident in Kenton’s ability to lead our commercial organization through our next phase of growth and am pleased to welcome him to the SMPA leadership team.”
With more than 30 years of leadership experience within commercial pharmaceutical and medical device companies, Stewart has previously served as executive vice president, market access and business development at California-based Urovant Sciences, which has since been acquired by SMPA, and as senior vice president, health systems business unit at Alkermes in Waltham.
As SMPA’s first CCO, Stewart will take over the responsibilities of Adele Gulfo, CEO of the company’s biopharma commercial unit, who will leave SMPA, effective Sept. 30.
Stewart earned his bachelor’s degree from Wichita State University in Kansas and his master’s from Bellevue University in Nebraska.
“It is my pleasure and privilege to lead our commercial organization, and I am deeply aligned with our company’s mission to develop novel medicines that help address unmet needs,” Stewart said in the release. “We are one team with one mission and I look forward to continuing to partner with my colleagues to advance our business and deliver for our patients.”
Sumitomo Pharma America is a subsidiary of Japan conglomerate Sumitomo Pharma Co. Among the products from the American division is a drug to treat leukemia.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments